Health platform now offering compounded Ozempic and Wegovy at reduced prices

[Duaine]

While shortages of the popular weight loss drugs persist, Hims & Hers, a San Francisco-based telehealth company, will offer access to a compounded form of the GLP-1 weight-loss drugs, starting at $199 a month.

Hims & Hers, a San Francisco-based health and wellness platform, announced last month that it will offer access to a compounded GLP-1 weight-loss injections at a competitive price.
"Starting today, we are providing access to compounded GLP-1 treatments for eligible customers at prices starting at $199 monthly," the company said in a news release. "We are providing access to compounded GLP-1s, which means customers can access the same active ingredient as Ozempic and Wegovy without navigating the shortages that are currently limiting access to the medication."
GLP-1 drugs, which are used for both diabetes and obesity, are in strong demand as manufacturers scramble to ramp up supply. Ozempic maker Novo Nordisk said earlier that shortages of the drug will persist through the year because of rising demand and manufacturing capacity constraints.

[EXTERNAL LINK] - Health platform now offering compounded Ozempic and Wegovy at reduced prices

 

[Northeast Agent]

Weight-Loss Drugmakers Are Overcharging By 400%; Here’s A Quick Solution

Congress can implement a quick and simple solution to make GLP-1 drugs affordable.

www.forbes.com

Hims & Hers is able to sell its version of these patented weight-loss drugs because Congress has authorized the compounding and sale of a patented drug when there is an FDA-determined drug shortage. However, once the GLP-1 shortage is resolved, companies like Hims & Hers will be required to cease production. This will compromise the health of current users and price out many more Americans still struggling to lose weight